Is eNAMPT/visfatin a potential serum marker of papillary thyroid cancer?

Nadia Sawicka-GutajPaulina ZiółkowskaAleksandra DerwichPaweł GutAgata CzarnywojtekMichał KloskaMarek Ruchała

Published in: Therapeutic advances in endocrinology and metabolism (2022)

We have not found visfatin as a potential serum marker of papillary thyroid cancer. Also, eNAMPT has no prognostic value in assessing the risk of disease recurrence or metastasis in PTC management.

Keyphrases

human health
clear cell
risk assessment